Primary Biliary Cirrhosis Drugs Market Business Segmentation By Revenue And Structure Forecast 2027

 


Primary biliary cirrhosis (PBC) also called primary biliary cholangitis is an autoimmune disease of liver, which causes liver inflammation, fibrosis, and obstruction in the bile duct leading to destruction of small bile ducts within liver. PBC causes autoimmunity, infection and/or genetic predisposition. The primary symptoms of primary biliary cirrhosis are itching, osteoporosis, elevated serum cholesterol, and malabsorption of fat and fat soluble vitamins, which can advance to hepatomegaly, hyperpigmentation, splenomegaly, jaundice, sicca syndrome or Kayser-Fleischer rings.


Primary Biliary Cirrhosis Drugs Market The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market. Various non-profit organizations are also operating awareness programs and funding research on novel therapies to treat the condition. This will foster market growth. The Global Primary Biliary Cirrhosis Drug Market report provides a holistic evaluation of the market. The rising awareness campaigns to reduce further complications in the primary biliary cholangitis indication is one of the key factors driving the global market.


Primary Biliary Cirrhosis Drugs Market – Competitor


Key players in the primary biliary cirrhosis drugs market are Dr. Falk Pharma GmbH, Intercept Pharmaceuticals, Inc., Enanta Pharmaceuticals, Inc , GlaxoSmithKline Plc, and Johnson & Johnson.


Primary Biliary Cirrhosis Drugs Market – Driver


However, large number of drugs are in clinical trials and this is expected to propel growth of the primary biliary cirrhosis drug market in the near future. NGM282 has a unique opportunity to leverage the dual targets of FGF19 without the potential non-tumorigenic property. For instance, in 2017, NGM Biopharmaceuticals, Inc. completed phase II clinical trials for its candidate drug NGM 282, an engineered variant of human hormone FGF19, to eliminate bile acid toxicity in primary biliary cirrhosis patients.


Comments

Popular posts from this blog

Security Robot Market is Estimated To Witness High Growth Owing To Increasing Demand for Enhanced Surveillance

The Ever-Evolving Landscape of the Scottish Whisky Market during the Forecast Period 2019-2027

Monochloroacetic Acid (MCAA) Market Is Estimated To Witness High Growth Owing To Increasing Demand for Surfactants and Herbicides